Astellas Pharma (4503) · InitiativeAchieved
Termination of the technology licensing agreement with Immunomic Therapeutics for a Japanese cedar pollen allergy treatment vaccine
First written in FY2021-Q3. 1 of 1 entries say "Achieved", first in FY2021-Q3. Latest entry: FY2021-Q3.
1entries
1years
0from disclosures
How it moved
Same theme, other companies
Termination of the technology licensing agreement with Immunomic Therapeutics for Japanese cedar pollen allergy vaccine technologyA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.